Journal of Thrombosis and Haemostasis

Discovery of ₂-plasmin inhibitor and its congenital deficiency
pp. 623-631(9)
Author: Aoki, N.

Fibrinogen measurement to assess the risk of arterial thrombosis in individual patients: yes
pp. 632-634(3)
Author: MEADE, T.W.

Fibrinogen measurement to assess the risk of arterial thrombosis in individual patients: not yet
pp. 635-637(3)
Author: LOWE, G. D. O.

When all else fails to stop massive bleeding from trauma
pp. 638-639(2)
Author: THOMPSON, ARTHUR R.

Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force
pp. 640-648(9)
Authors: MARTINOWITZ, U.; MICHAELSON, M.

The quest for the Holy Grail of tissue factor pathway inhibitor deficiency has just begun
pp. 649-650(2)
Authors: ARIËNS, R. A. S.

A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI)
pp. 651-658(8)
Authors: DAHM, A. E. A.; ANDERSEN, T. O.; ROSENDAAL, F.; SANDSET, P. M.

Plasma von Willebrand factor levels and surrogates of atherosclerosis
pp. 659-661(3)
Authors: LIP, G. Y. H.; FOSTER, W.; BLANN, A. D.

Independent association of von Willebrand factor with surrogate markers of atherosclerosis in middle-aged asymptomatic subjects
pp. 662-664(3)
Authors: PÁRAMO, J. A.; BELOQUI, O.; COLINA, I.; DIEZ, J.; ORBE, J.

Variability in response to aspirin: do we understand the clinical relevance?
pp. 665-669(5)
Authors: CAMPBELL, C. L.; STEINHUBL, S. R.

Two faces of high-molecular-weight kininogen (HK) in angiogenesis: bradykinin turns it on and cleaved HK (HKa) turns it off
pp. 670-676(7)
Authors: GUO, Y-L.; COLMAN, R. W.

Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis
pp. 677-685(9)
Authors: WIBAUT-BERLAIMONT, V.; RANDI, A. M.; MANDRYKO, V.; LUNNON, M. W.; HASKARD, D. O.; NAOUMOVA, R. P.

The G20210A prothrombin-gene mutation and the plasminogen activator inhibitor (PAI-1) 5G/5G genotype are associated with early onset of severe preeclampsia
pp. 686-691(6)
Authors: GERHARDT, A.; GOECKE, T. W.; BECKMANN, M. W.; WAGNER, K. J.; TUTSCHEK, B.; WILLERS, R.; BENDER, H-G.; SCHARF, R. E.; ZOTZ, R. B.

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
pp. 692-694(3)
Authors: SCHULMAN, S.; KEARON, C.

Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice
pp. 695-702(8)
Authors: WANG, X.; CHENG, Q.; XU, L.; FEUERSTEIN, G. Z.; HSU, M-Y.; SMITH, P. L.; SEIFFERT, D. A.; SCHUMACHER, W. A.; OGLETREE, M. L.; GAILANI, D.

Clinical outcome of patients with venous thromboembolism and recent major bleeding: findings from a prospective registry (RIETE)
pp. 703-709(7)
Authors: NIETO, J. A.; DE TUESTA, A. D.; MARCHENA, P. J.; TIBERIO, G.; TODOLI, J. A.; SAMPERIZ, A. L.; MONREAL, M.

Thrombomodulin gene polymorphisms or haplotypes as potential risk factors for venous thromboembolism: a population-based case–control study
pp. 710-717(8)
Authors: HEIT, JOHN A.; PETTERSON, TANYA M.; OWEN, WHYTE G.; BURKE, JAMES P.; DE ANDRADE, MARIZA; MELTON, L. JOSEPH

Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis
pp. 718-723(6)
Authors: KAHN, S. R.; KEARON, C.; JULIAN, J. A.; MACKINNON, B.; KOVACS, M. J.; WELLS, P.; CROWTHER, M. A.; ANDERSON, D. R.; VAN NGUYEN, P.; DEMERS, C.; SOLYMOSS, S.; KASSIS, J.; GEERTS, W.; RODGER, M.; HAMBLETON, J.; GINSBERG, J. S.

Liver histology of an afibrinogenemic patient with the B-L353R mutation showing no evidence of hepatic endoplasmic reticulum storage disease (ERSD); comparative study in COS-1 cells of the intracellular processing of the B-L353R fibrinogen vs. the ERSD-associated -G284R mutant
pp. 724-732(9)
Authors: DUGA, S.; BRAIDOTTI, P.; ASSELTA, R.; MAGGIONI, M.; SANTAGOSTINO, E.; PELLEGRINI, C.; COGGI, G.; MALCOVATI, M.; TENCHINI, M. L.

Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic responses
pp. 733-741(9)
Authors: GOULD, W. R.; BAXI, S. M.; SCHROEDER, R.; PENG, Y. W.; LEADLEY, R. J.; PETERSON, J. T.; Perrin, L. A.

Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count
pp. 742-751(10)
Authors: LISMAN, T.; ADELMEIJER, J.; CAUWENBERGHS, S.; VAN PAMPUS, E. C. M.; HEEMSKERK, J. W. M.; DE GROOT, P. G.

Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: implications for the pathophysiology of hemolytic uremic syndrome
pp. 752-762(11)
Authors: NESTORIDI, E.; TSUKUROV, O.; KUSHAK, R. I.; INGELFINGER, J. R.; GRABOWSKI, E. F.

SHPS-1 negatively regulates integrin _IIb3 function through CD47 without disturbing FAK phosphorylation
pp. 763-774(12)
Authors: KATO, HISASHI; HONDA, SHIGENORI; YOSHIDA, HITOSHI; KASHIWAGI, HIROKAZU; SHIRAGA, MASAMICHI; HONMA, NAKAYUKI; KURATA, YOSHIYUKI; TOMIYAMA, YOSHIAKI

Provisional criteria for the diagnosis of VWD type 1: on behalf of the ISTH SSC Subcommittee on von Willebrand Factor
pp. 775-777(3)
Authors: SADLER, J. E.; RODEGHIERO, F.

The use of LMWH in pregnancies at risk: new evidence or perception?
pp. 778-779(2)
Author: WALKER, I. D.

The use of LMWH in pregnancies at risk: new evidence or perception?
pp. 779-780(2)
Author: KUJOVICH, J. L.

The use of LMWH in pregnancies at risk: new evidence or perception?
pp. 781-782(2)
Author: GREER, I. A.

The use of LMWH in pregnancies at risk: new evidence or perception?
pp. 782-783(2)
Authors: REY, E.; DAVID, M.

The use of LMWH in pregnancies at risk: new evidence or perception?
pp. 783-785(3)
Author: SALMON, J. E.

The use of LMWH in pregnancies at risk: new evidence or perception?
pp. 785-786(2)
Author: HUNT, B. J.

The use of LMWH in pregnancies at risk: new evidence or perception?
pp. 787-788(2)
Authors: ZOTZ, R. B.; GERHARDT, A.; SCHARF, R. E.

The use of LMWH in pregnancies at risk: new evidence or perception?
pp. 788-789(2)
Author: MIDDELDORP, S.

The use of LMWH in pregnancies at risk: new evidence or perception?
pp. 789-790(2)
Author: MARTINELLI, I.

The use of LMWH in pregnancies at risk: new evidence or perception?
pp. 791-792(2)
Author: CETIN, I.

The use of LMWH in pregnancies at risk: new evidence or perception?
pp. 792-793(2)
Author: GRANDONE, E.

Plasma von Willebrand factor and arterial aging
pp. 794-795(2)
Authors: VISCHER, U. M.; HERRMANN, F. R.; PEYRARD, T.; NZIETCHUENG, R.; BENETOS, A.

Theoretical structural explanation for Group I and Group II, type 2A von Willebrand disease mutations
pp. 796-797(2)
Authors: O'BRIEN, L. A.; SUTHERLAND, J. J.; WEAVER, D. F.; LILLICRAP, D.

Evaluation of the von Willebrand factor Y1584C polymorphism as a potential risk factor for bleeding in patients receiving anticoagulant treatment with vitamin K antagonists
pp. 797-798(2)
Authors: TJERNBERG, P.; VAN DER HEIJDEN, J. F.; EIKENBOOM, J. C. J.; REITSMA, P. H.

Inhibitor to factor VII in severe factor VII deficiency: detection and course of the inhibitory response
pp. 799-800(2)
Authors: INGERSLEV, J.; CHRISTIANSEN, K.; SØRENSEN FOR THE INTERNATIONAL REGISTRY ON FACTOR VII DEFICIENCY IRF7 STEERING COMMITTEE, B.

Genetic variation in alcohol dehydrogenase 3 and the decrease of hs-C-reactive protein levels by moderate alcohol consumption
pp. 801-802(2)
Authors: FURMAN, K.; DI CASTELNUOVO, A.; ZITO, F.; DE GAETANO, G.; IACOVIELLO, L.

Factor VII gene polymorphisms are not associated with myocardial infarction in young women
pp. 803-804(2)
Authors: PEYVANDI, F.; BERNARDINELLI, L.; MARTINI, C. H.; CELLI, P.; MANNUCCI, P. M.

Absence of Pro475Ser polymorphism in ADAMTS-13 in Caucasians
pp. 805-805(1)
Authors: BONGERS, T. N.; DE MAAT, M. P. M.; DIPPEL, D. W. J.; UITTERLINDEN, A. G.; LEEBEEK, F. W. G.

Functional analysis of two polymorphisms in the 3-UTR of the human prothrombin gene
pp. 806-808(3)
Authors: CEELIE, H.; SPAARGAREN-VAN RIEL, C. C.; LYON, E.; BERTINA, R. M.; VOS, H. L.

Novel missense mutations in two patients with factor XI deficiency (Val271Leu and Tyr351Ser) and one patient with combined factor XI and factor IX deficiency (Phe349Val)
pp. 808-811(4)
Authors: JAYANDHARAN, G.; SHAJI, R. V.; NAIR, S. C.; CHANDY, M.; SRIVASTAVA, A.

Thrombophilia and venous thromboembolism after total hip or knee replacement surgery: a systematic review
pp. 811-813(3)
Authors: WU, O.; CLARK, P.; LOWE, G. D. O.; WALKER, I. D.; GREER, I. A.

More on: diagnosing pulmonary embolism in pregnancy: rationalizing fetal radiation exposure in radiological procedures
pp. 813-814(2)
Authors: LE GAL, G.; RIGHINI, M.

More on: Diagnosing pulmonary embolism with helical computed tomography during pregnancy: what about exposure to iodinated contrast agents?
pp. 814-815(2)
Authors: NIJKEUTER, M.; HUISMAN, M. V.

Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology—a rebuttal
pp. 816-817(2)
Authors: VASVARI, G.; DYCKHOFF, G.; HEROLD-MENDE, C.

Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology—reply to a rebuttal
pp. 817-818(2)
Author: KAUSHAL, V.

Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity—a rebuttal
pp. 818-819(2)
Authors: MAKRIS, M.; VAN VEEN, J. J.

Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity—reply to a rebuttal
pp. 819-819(1)
Author: ALEDORT, L. M.

Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity—a rebuttal
pp. 820-822(3)
Authors: SALLAH, S.; ISAKSEN, M.; SEREMETIS, S.; PAYNE ROJKJAER, L.

Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity—reply to a rebuttal
pp. 822-822(1)
Author: ALEDORT, L. M.

Book Review
pp. 823-824(2)

Talking about …
pp. 825-827(3)
Authors: BRUTTOMESSO, G.; MIGLINO, N.

Announcements
pp. 828-828(1)

Corrigendum
pp. 829-829(1)